Related Experiment Video
Updated: Jun 17, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
[IgA multiple myeloma with adverse prognostic factors--a case report]
Beata Kumiega1, Teresa Wolska-Smoleń, Aleksander B Skotnicki
1Oddział Chorób Wewnetrznych z Pododdziałem Hematologii Wojewódzkiego Szpitala Podkarpackiego w Krośnie. bkumiega@interia.pl
Przeglad Lekarski
|January 2, 2010
Summary
IgA multiple myeloma, a common variant, has poor prognosis linked to chromosome 13 alterations. This case highlights resistance to novel therapies, underscoring challenges in treating this aggressive myeloma subtype.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Immunoglobulin A (IgA) multiple myeloma is the second most common subtype.
- Prognosis is influenced by prognostic factors, with cytogenetic status being paramount.
- Chromosome 13 alterations are recognized as independent adverse prognostic markers.
Observation:
- This case involves IgA multiple myeloma with chromosome 13 alterations.
- The patient's condition was refractory to standard and novel therapeutic strategies.
- Resistance was observed even with treatments like thalidomide and bortezomib.
Findings:
- Chromosome 13 deletion in multiple myeloma correlates with poorer treatment response.
- Patients with chromosome 13 alterations exhibit significantly shorter median overall survival.
- This specific IgA myeloma case demonstrated resistance to cutting-edge treatments.
Implications:
- The findings emphasize the critical role of cytogenetic analysis in managing IgA multiple myeloma.
- Treatment strategies may need further refinement for patients with chromosome 13 alterations.
- Further research is warranted to overcome therapeutic resistance in aggressive myeloma subtypes.
